FUNDAMENTALS:
GILD ( Gilead Sciences ) is that company that found the cure for hepatitis C. The fundamentals are improving again. The industry has not done as well as in others. However, with the recent acquisition of MYR Pharmaceuticals (myr-pharma.com), GILD is currently in phase 3 for the treatment of hepatitis B and D.
***Revenue is also generated when more people catch and/or are dying of covid with their covid treatment called Veklury. Revenue soared around $1.5 billion from Veklury alone.
Target 80 or 165
GILD ( Gilead Sciences ) is that company that found the cure for hepatitis C. The fundamentals are improving again. The industry has not done as well as in others. However, with the recent acquisition of MYR Pharmaceuticals (myr-pharma.com), GILD is currently in phase 3 for the treatment of hepatitis B and D.
***Revenue is also generated when more people catch and/or are dying of covid with their covid treatment called Veklury. Revenue soared around $1.5 billion from Veklury alone.
Target 80 or 165
Capturing the swings of the stock market & currency market. It's a dirty job and equity/currency traders must do it.
Penerbitan berkaitan
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.
Capturing the swings of the stock market & currency market. It's a dirty job and equity/currency traders must do it.
Penerbitan berkaitan
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.